25 results on '"Mari, Andrea"'
Search Results
2. The optimal number of induction chemotherapy cycles in clinically lymph node‐positive bladder cancer.
- Author
-
von Deimling, Markus, Mertens, Laura S., Furrer, Marc, Li, Roger, Tendijck, Guus A.H., Taylor, Jacob, Crocetto, Felice, Maas, Moritz, Mari, Andrea, Pichler, Renate, Moschini, Marco, Tully, Karl H., D'Andrea, David, Laukhtina, Ekaterina, Del Giudice, Francesco, Marcq, Gautier, Velev, Maud, Gallioli, Andrea, Albisinni, Simone, and Mori, Keiichiro
- Subjects
INDUCTION chemotherapy ,BLADDER cancer ,LYMPHADENECTOMY ,LOGISTIC regression analysis ,SURVIVAL rate - Abstract
Objective: To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node‐positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection. Patients and Methods: We included 388 patients who received three or four cycles of cisplatin/gemcitabine or (dose‐dense) methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), followed by consolidative RC for cTanyN1–3M0 BCa. We compared pathological complete (pCR = ypT0N0) and objective response (pOR = yp ≤T1N0) between treatment groups. Predictors of pCR and/or pOR were assessed using uni‐ and multivariable logistic regression analysis. The secondary endpoints were overall (OS) and cancer‐specific survival (CSS). We evaluated the association between the number of induction chemotherapy cycles administered and survival outcomes on multivariable Cox regression. Results: Overall, 101 and 287 patients received three or four cycles of induction chemotherapy, respectively. Of these, 72 (19%) and 128 (33%) achieved pCR and pOR response, respectively. The pCR (20%, 18%) and pOR (40%, 31%) rates did not differ significantly between patients receiving three or four cycles (P > 0.05). The number of cycles was not associated with pCR or pOR on multivariable logistic regression analyses. The 2‐year OS estimates were 63% (95% confidence interval [CI] 0.53–0.74) and 63% (95% CI 0.58–0.7) for patients receiving three or four cycles, respectively. Receiving three vs four cycles was not associated with OS and CSS on uni‐ or multivariable Cox regression analyses. Conclusion: Pathological response and survival outcomes did not differ between administering three or four induction chemotherapy cycles in patients with cN+ BCa. A fewer cycles (minimum three) may be oncologically sufficient in patients with cN+ BCa, while decreasing the wait for definitive local therapy in those patients who end up without a response to chemotherapy. This warrants further validation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Variation in Follow-Up after Radical Cystectomy for Bladder Cancer—An Inventory Roundtable and Literature Review.
- Author
-
Contieri, Roberto, Pichler, Renate, del Giudice, Francesco, Marcq, Gautier, Gallioli, Andrea, Albisinni, Simone, Soria, Francesco, d'Andrea, David, Krajewski, Wojciech, Carrion, Diego M., Mari, Andrea, van Rhijn, Bas W. G., Moschini, Marco, Pradere, Benjamin, and Mertens, Laura S.
- Subjects
LITERATURE reviews ,BLADDER cancer ,CYSTECTOMY ,TRANSITIONAL cell carcinoma ,INVENTORIES ,COMPUTED tomography - Abstract
Background: Follow-up after radical cystectomy (RC) for bladder cancer can be divided into oncological and functional surveillance. It remains unclear how follow-up after RC should ideally be scheduled. The aim of this report was to gain insight into the organization of follow-up after RC in Europe, for which we conducted a roundtable inventory within the EAU Young Academic Urologists Urothelial Cancer working group. Methods: An inventory semi-structured survey was performed among urologists of the EAU Young Academic Urologists Urothelial Cancer working group to describe the organization of follow-up. The surveys were analyzed using a deductive approach. Similarities and differences in follow-up after RC for bladder cancer were described. Results: The survey included 11 urologists from six different European countries. An institutional follow-up scheme was used by six (55%); three (27%) used a national or international guideline, and two (18%) indicated that there was no defined follow-up scheme. Major divergent aspects included the time points of follow-up, the frequency, and the end of follow-up. Six centers (55%) adopted a risk-adapted follow-up approach tailored to (varying) patient and tumor characteristics. Laboratory tests and CT scans were used in all cases; however, the intensity and frequency varied. Functional follow-up overlapped with oncological follow-up in terms of frequency and duration. Patient-reported outcome measures were only used by two (18%) urologists. Conclusions: Substantial variability exists across European centers regarding the follow-up after RC for bladder cancer. This highlights the need for an international analysis focusing on its organization and content as well as on opportunities to improve patients' needs during follow-up after RC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid Instillations in Bladder Cancer.
- Author
-
Pichler, Renate, Stäblein, Johannes, Mari, Andrea, Afferi, Luca, D'Andrea, David, Marcq, Gautier, del Giudice, Francesco, Soria, Francesco, Caño-Velasco, Jorge, Subiela, José Daniel, Gallioli, Andrea, Tully, Karl H., Mori, Keiichiro, Herms, Achim, Pradere, Benjamin, Moschini, Marco, Mertens, Laura S., and Thurnher, Martin
- Subjects
BLADDER cancer ,NON-muscle invasive bladder cancer ,HYALURONIC acid ,CHONDROITIN ,CYSTITIS ,BCG immunotherapy - Abstract
In non-muscle invasive bladder cancer, Bacillus Calmette–Guérin (BCG) responders benefit from strong Th1-type inflammatory and T cell responses mediating tumor rejection. However, the corresponding lack of anti-inflammatory Th2-type immunity impairs tissue repair in the bladder wall and facilitates the development of cystitis, causing urinary pain, urgency, incontinence, and frequency. Mechanistically, the leakage of the glycosaminoglycan (GAG) layer enables an influx of potassium ions, bacteria, and urine solutes towards the underlying bladder tissue, promoting chronic inflammation. Treatments directed towards re-establishing this mucopolysaccharide-based protective barrier are urgently needed. We discuss the pathomechanisms, as well as the therapeutic rationale of how chondroitin and hyaluronic acid instillations can reduce or prevent BCG-induced irritative bladder symptoms. Moreover, we present a case series of five patients with refractory BCG-induced cystitis successfully treated with combined chondroitin and hyaluronic acid instillations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node‐positive bladder cancer.
- Author
-
von Deimling, Markus, Furrer, Marc, Mertens, Laura S., Mari, Andrea, van Ginkel, Noor, Bacchiani, Mara, Maas, Moritz, Pichler, Renate, Li, Roger, Moschini, Marco, Bianchi, Alberto, Vetterlein, Malte W., Lonati, Chiara, Crocetto, Felice, Taylor, Jacob, Tully, Karl H., Afferi, Luca, Soria, Francesco, del Giudice, Francesco, and Longoni, Mattia
- Subjects
LYMPHADENECTOMY ,SURVIVAL rate ,BLADDER cancer ,INDUCTION chemotherapy ,LOGISTIC regression analysis - Abstract
Objective: To determine the oncological impact of extended pelvic lymph node dissection (ePLND) vs standard PLND (sPLND) during radical cystectomy (RC) in clinically lymph node‐positive (cN+) bladder cancer (BCa). Patients and Methods: In this retrospective, multicentre study we included 969 patients who underwent RC with sPLND (internal/external iliac and obturator lymph nodes) or ePLND (sPLND plus common iliac and presacral nodes) with or without platin‐based peri‐operative chemotherapy for cTany N1‐3 M0 BCa between 1991 and 2022. We assessed the impact of ePLND on recurrence‐free survival (RFS) and the distribution of recurrences (locoregional and distant recurrences). The secondary endpoint was overall survival (OS). We performed propensity‐score matching using covariates associated with the extent of PLND in univariable logistic regression analysis. The association of the extent of PLND with RFS and OS was investigated using Cox regression models. Results: Of 969 cN+ patients, 510 were 1:1 matched on propensity scores. The median (interquartile range [IQR]) time to recurrence was 8 (4–16) months, and median (IQR) follow‐up of alive patients was 30 (13–51) months. Disease recurrence was observed in 104 patients in the ePLND and 107 in the sPLND group. Of these, 136 (27%), 47 (9.2%) and 19 patients (3.7%) experienced distant, locoregional, or both distant and locoregional disease recurrence, respectively. When stratified by the extent of PLND, we did not find a difference in recurrence patterns (P > 0.05). ePLND improved neither RFS (hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.70–1.19; P = 0.5) nor OS (HR 0.78, 95% CI 0.60–1.01; P = 0.06) compared to sPLND. Stratification by induction chemotherapy did not change outcomes. Conclusion: Performing an ePLND at the time of RC in cN+ patients improved neither RFS nor OS compared to sPLND, regardless of induction chemotherapy status. Pretreatment risk stratification is paramount to identify ideal candidates for RC with ePLND as part of a multimodal treatment approach. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2.
- Author
-
Pichler, Renate, Diem, Gabriel, Hackl, Hubert, Koutník, Jiří, Mertens, Laura S., D'Andrea, David, Pradere, Benjamin, Soria, Francesco, Mari, Andrea, Laukhtina, Ekaterina, Krajewski, Wojciech, Jeremy Yuen-Chun Teoh, Del Guidice, Francesco, Moschini, Marco, Thurnher, Martin, and Posch, Wilfried
- Subjects
BCG vaccines ,BCG immunotherapy ,IMMUNE response ,MONONUCLEAR leukocytes ,BLADDER cancer ,SARS-CoV-2 - Abstract
BCG is the most efficient adjuvant therapy for high-risk, non-muscle-invasive bladder cancer (NMIBC). Both innate and adaptive immune responses have been implicated in BCG-mediated effects. BCG vaccination can boost innate immune responses via trained immunity (TI), resulting in an increased resistance to respiratory viral infections. Here we evaluated for the first time whether intravesical application of BCG triggers increased immunity against SARS-CoV-2 in patients with high-risk NMIBC. Serum and peripheral blood mononuclear cells (PBMCs) from heparinized whole blood samples of 11 unvaccinated SARSCoV-2-naïve high-risk NMIBC patients were collected at baseline and during BCG treatment in a pre-COVID-19 era. To examine B-cell or T cell-dependent adaptive immunity against SARS-CoV-2, sera were tested for the presence of SARS-CoV-2 neutralizing antibodies. Using a SARS-CoV-2 peptide pool, virusspecific T cells were quantified via IFNg ELISpot assays. To analyze innate immune responses, mRNA and protein expression levels of pro- and anti-inflammatory cytokines were measured after a 24-hour stimulation of PBMCs with either BCG or SARS-CoV-2 wildtype. ATAC-sequencing was performed to identify a potential epigenetic reprogramming in immune cells. We neither identified SARS-CoV-2 neutralizing antibodies nor SARS-CoV-2-reactive T cells, indicating that intravesical BCG did not induce adaptive immunity against SARS-CoV-2. However, a significant increase in mRNA as well as protein expression of IL-1β, IL-6 and TNFa, which are key cytokines of trained immunity, could be observed after at least four intravesical BCG instillations. Genomic regions in the proximity of TI genes (TLR2, IGF1R, AKT1, MTOR, MAPK14, HSP90AA1) were more accessible during BCG compared to baseline. Although intravesical BCG did not induce adaptive immune responses, repetitive intravesical instillations of BCG induced circulating innate immune cells that produce TI cytokines also in response to SARS-CoV-2. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence.
- Author
-
Bacchiani, Mara, Salamone, Vincenzo, Massaro, Eleana, Sandulli, Alessandro, Mariottini, Riccardo, Cadenar, Anna, Di Maida, Fabrizio, Pradere, Benjamin, Mertens, Laura S., Longoni, Mattia, Krajewski, Wojciech, Del Giudice, Francesco, D'Andrea, David, Laukhtina, Ekaterina, Shariat, Shahrokh F., Minervini, Andrea, Moschini, Marco, and Mari, Andrea
- Subjects
BLADDER tumors ,ONLINE information services ,MEDICAL information storage & retrieval systems ,SYSTEMATIC reviews ,METASTASIS ,LYMPH nodes ,TUMOR classification ,RADIOPHARMACEUTICALS ,POSITRON emission tomography ,DEOXY sugars ,COMPUTED tomography ,PHYSICIANS ,MEDLINE ,SENSITIVITY & specificity (Statistics) ,COMBINED modality therapy - Abstract
Simple Summary: Lymph node involvement is a prognostic determinant in the diagnostic work-up and management of muscle-invasive bladder cancer. Thus, it is crucial to provide an accurate staging of the bladder tumor to better identify the best therapeutic strategies to improve the chances of survival and the quality of life of patients affected by bladder cancer. Positron Emission Tomography/Computed Tomography (PET/CT) has been increasingly used in bladder cancer staging to improve the accuracy of lymph node detection and to overcome the lack of sensitivity and the understaging showed by conventional imaging. The aim of this narrative literature review is to provide an overview of the current evidence on the use of 18F-FDG PET/CT in the diagnosis, staging, and restaging of bladder cancer, with a particular focus on its sensitivity and specificity for the detection of LN metastasis. We aim to provide clinicians with a better understanding of 18F-FDG PET/CT's potential benefits and limitations in clinical practice. Despite the heterogeneity of the studies in the literature and the lack of a consensus, 18F-FDG PET/CT provides important incremental staging and restaging information that can potentially influence the clinical management of patients affected by muscle-invasive bladder cancer. Introduction: Lymph node (LN) involvement is a crucial determinant of prognosis for patients with bladder cancer, and an accurate staging is of utmost importance to better identify timely and appropriate therapeutic strategies. To improve the accuracy of LN detection, as an alternative to traditional methods such as CT or MRI, 18F-FDG PET/CT has been increasingly used. 18F-FDG PET/CT is also used in post-treatment restaging after neoadjuvant chemotherapy. The aim of this narrative literature review is to provide an overview of the current evidence on the use of 18F-FDG PET/CT in the diagnosis, staging, and restaging of bladder cancer, with a particular focus on its sensitivity and specificity for the detection of LN metastasis. We aim to provide clinicians with a better understanding of 18F-FDG PET/CT's potential benefits and limitations in clinical practice. Materials and Methods: We designed a narrative review starting from a wide search in the PubMed/MEDLINE and Embase databases, selecting full-text English articles that have examined the sensibility and specificity of PET/CT for nodal staging or restaging after neoadjuvant therapy in patients with bladder cancer. The extracted data were analyzed and synthesized using a narrative synthesis approach. The results are presented in a tabular format, with a summary of the main findings of each study. Results: Twenty-three studies met the inclusion criteria: fourteen studies evaluated 18F-FDG PET/CT for nodal staging, six studies examined its accuracy for restaging after neoadjuvant therapy, and three studies evaluated both applications. To date, the use of F-18 FDG PET/TC for detection of LN metastasis in bladder cancer is controversial and uncertain: some studies showed low accuracy rates, but over the years other studies have reported evidence of high sensitivity and specificity. Conclusions: 18F-FDG PET/CT provides important incremental staging and restaging information that can potentially influence clinical management in MIBC patients. Standardization and development of a scoring system are necessary for its wider adoption. Well-designed randomized controlled trials in larger populations are necessary to provide consistent recommendations and consolidate the role of 18F-FDG PET/CT in the management of bladder cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Impact of smoking on urologic cancers: a snapshot of current evidence.
- Author
-
Kumar, Raj, Matulewicz, Richard, Mari, Andrea, Moschini, Marco, Ghodoussipour, Saum, Pradere, Benjamin, Rink, Michael, Autorino, Riccardo, Desai, Mihir M., Gill, Inderbir, and Cacciamani, Giovanni E.
- Subjects
SMOKING cessation ,SMOKING ,PROSTATE cancer ,BLADDER cancer ,TOBACCO smoke ,DISEASE relapse ,LYMPHATIC metastasis - Abstract
Purpose: The purpose of this paper is to present evidence regarding the associations between smoking and the following urologic cancers: prostate, bladder, renal, and upper tract urothelial cancer (UTUC). Methods: This is a narrative review. PubMed was queried for evidence-based analyses and trials regarding the associations between smoking and prostate, bladder, renal, and UTUC tumors from inception to September 1, 2022. Emphasis was placed on articles referenced in national guidelines and protocols. Results: Prostate—multiple studies associate smoking with higher Gleason score, higher tumor stage, and extracapsular invasion. Though smoking has not yet been linked to tumorigenesis, there is evidence that it plays a role in biochemical recurrence and cancer-specific mortality. Bladder—smoking is strongly associated with bladder cancer, likely due to DNA damage from the release of carcinogenic compounds. Additionally, smoking has been linked to increased cancer-specific mortality and higher risk of tumor recurrence. Renal—smoking tobacco has been associated with tumorigenesis, higher tumor grade and stage, poorer mortality rates, and a greater risk of tumor recurrence. UTUC—tumorigenesis has been associated with smoking tobacco. Additionally, more advanced disease, higher stage, lymph node metastases, poorer survival outcomes, and tumor recurrence have been linked to smoking. Conclusion: Smoking has been shown to significantly affect most urologic cancers and has been associated with more aggressive disease, poorer outcomes, and tumor recurrence. The role of smoking cessation is still unclear, but appears to provide some protective effect. Urologists have an opportunity to engage in primary prevention by encouraging cessation practices. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators.
- Author
-
Del Giudice, Francesco, D'Andrea, David, Pradere, Benjamin, Berndl, Florian, Pallauf, Maximilian, Flammia, Rocco Simone, Philipp, Dominik, Moschini, Marco, Mari, Andrea, Albisinni, Simone, Krajewski, Wojciech, Laukhtina, Ekaterina, Gallioli, Andrea, Mertens, Laura S., Marcq, Gautier, Cimadamore, Alessia, Afferi, Luca, Gontero, Paolo, Shariat, Shahrokh F., and Chung, Benjamin I.
- Subjects
TRANSURETHRAL resection of bladder ,BLADDER cancer ,TUMOR surgery ,TRANSURETHRAL prostatectomy ,EXPERTISE ,UROLOGY ,CANCER invasiveness - Abstract
Objectives To address the association of perioperative surgical checklist across variable surgical expertise with transurethral resection of bladder tumour (TURBT) accuracy and oncological outcomes in non-muscle-invasive bladder cancer. Patients and Methods We relied on our prospective collaborative database of patients treated with TURBT between 2012 and 2017. Surgical experience was stratified into three groups: resident vs young vs expert consultants. The association of surgical experience with detrusor muscle (DM) presence and adherence to the standardised peri-procedural nine-items TURBT checklist was evaluated with logistic regression models. A Cox regression model was used to investigate the association of surgical experience with recurrence-free survival (RFS). Results A total of 503 patients were available for analysis. TURBT was performed by expert consultants in 265 (52.7%) patients, by young consultants in 149 (29.6%) and by residents in 89 (17.7%). Residents were more likely to have DM in the TURBT specimen than expert consultants (odds ratio [OR] 1.75, 95% confidence interval [CI] 1.03-2.99, P = 0.04). Conversely, no differences in DM presence were seen between young vs expert consultants (OR 1.09, 95% CI 0.71-1.70, P = 0.69). The median checklist completion rate was higher for both residents and young consultants when compared to experts' counterparts (56% and 56% vs 44%, P = 0.009). When focusing on patients receiving a second-look TURBT, the persistent disease was associated with resident status (OR 4.24, 95% CI 1.14-17.70, P = 0.037) at initial TURBT. Surgical experience was not associated with 5-years RFS. Conclusion Surgeon's experience in the case of adequate perioperative surgical checklist implementation was inversely associated with the presence of DM in the specimen but directly linked to higher probability of persistent disease at re-TURBT, although no 5-year RFS differences were noted. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis.
- Author
-
Del Giudice, Francesco, Asero, Vincenzo, Bologna, Eugenio, Scornajenghi, Carlo Maria, Carino, Dalila, Dolci, Virginia, Viscuso, Pietro, Salciccia, Stefano, Sciarra, Alessandro, D'Andrea, David, Pradere, Benjamin, Moschini, Marco, Mari, Andrea, Albisinni, Simone, Krajewski, Wojciech, Szydełko, Tomasz, Małkiewicz, Bartosz, Nowak, Łukasz, Laukhtina, Ekaterina, and Gallioli, Andrea
- Subjects
ONLINE information services ,MEDICAL databases ,META-analysis ,MEDICAL information storage & retrieval systems ,CONFIDENCE intervals ,SYSTEMATIC reviews ,CANCER relapse ,REGRESSION analysis ,NON-muscle invasive bladder cancer ,BCG vaccines ,QUALITY assurance ,DESCRIPTIVE statistics ,MEDLINE - Abstract
Simple Summary: Bacillus of Calmette-Guérin (BCG) is the gold standard as per adjuvant intravesical treatment for intermediate and high-risk non-muscle invasive bladder cancer (NMIBC). Nevertheless, drug-related toxicity, compliance, and a shortage of BCG availability make the completion of the planned treatment schedule challenging in many patients, thus possibly impacting survival outcomes. No one specific BCG strain out of the several available ones worldwide has so far demonstrated its superiority profile in prolonging time to recurrence and progression. In our systematic review and network meta-analysis, we compared to most widely adopted BCG strains and demonstrated that BCG strain Tice, RIVM, and Tokyo 172 could display potential enhanced benefits, thus possibly supporting the use of such strains for future BCG trials in NMIBCs. Background: In an era of Bacillus of Calmette-Guérin (BCG) shortages, the comparative efficacy from different adjuvant intravesical BCG strains in non-muscle invasive bladder cancer (NMIBC) has not been clearly elucidated. We aim to compare, through a systematic review and meta-analysis, the cumulative BC recurrence rates and the best efficacy profile of worldwide available BCG strains over the last forty years. Methods: PubMed, Scopus, Web of Science, Embase, and Cochrane databases were searched from 1982 up to 2022. A meta-analysis of pooled BC recurrence rates was stratified for studies with ≤3-y vs. >3-y recurrence-free survival (RFS) endpoints and the strain of BCG. Sensitivity analysis, sub-group analysis, and meta-regression were implemented to investigate the contribution of moderators to heterogeneity. A random-effect network meta-analysis was performed to compare BCG strains on a multi-treatment level. Results: In total, n = 62 series with n = 15,412 patients in n = 100 study arms and n = 10 different BCG strains were reviewed. BCG Tokyo 172 exhibited the lowest pooled BC recurrence rate among studies with ≤3-y RFS (0.22 (95%CI 0.16–0.28). No clinically relevant difference was noted among strains at >3-y RFS outcomes. Sub-group and meta-regression analyses highlighted the influence of NMIBC risk-group classification and previous intravesical treated categories. Out of the n = 11 studies with n = 7 BCG strains included in the network, BCG RIVM, Tice, and Tokyo 172 presented with the best-predicted probability for efficacy, yet no single strain was significantly superior to another in preventing BC recurrence risk. Conclusion: We did not identify a BCG stain providing a clinically significant lower BC recurrence rate. While these findings might discourage investment in future head-to-head randomized comparison, we were, however, able to highlight some potential enhanced benefits from the genetically different BCG RIVM, Tice, and Tokyo 172. This evidence would support the use of such strains for future BCG trials in NMIBCs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. PD34-12 THE OPTIMAL NUMBER OF INDUCTION CHEMOTHERAPY CYCLES IN CLINICALLY LYMPH NODE-POSITIVE BLADDER CANCER.
- Author
-
von Deimling, Markus, Mertens, Laura S., Furrer, Marc, Li, Roger, Tendijck, Guus A. H., Taylor, Jacob, Crocetto, Felice, Maas, Moritz, Mari, Andrea, Pichler, Renate, Moschini, Marco, Tully, Karl H., D'Andrea, David, Laukhtina, Ekaterina, Del Giudice, Francesco, Marcq, Gautier, Velev, Maud, Gallioli, Andrea, Albisinni, Simone, and Mori, Keiichiro
- Subjects
INDUCTION chemotherapy ,BLADDER cancer - Published
- 2024
- Full Text
- View/download PDF
12. MP38-20 RISK OF UPPER URINARY TRACT DISSEMINATION IN cT3 BLADDER CANCER PATIENTS TREATED WITH DOUBLE-J STENT VERSUS NEPHROSTOMY TUBE PRIOR TO RADICAL CYSTECTOMY.
- Author
-
de Angelis, Mario, Soria, Francesco, Pradere, Benjamin, Afferi, Luca, Montorsi, Francesco, Briganti, Alberto, Shariat, Shahrokh F., Wiklund, Peter, D'Andrea, David, Albissini, Simone, Mari, Andrea, Del Giudice, Francesco, Krajewski, Wojciech, Laukhtina, Ekaterina, Yuen-Chun Teoh, Jeremy, Mori, Keiichiro, Mertens, Laura S., Gallioli, Andrea, Pichler, Renate, and Moschini, Marco
- Subjects
URINARY organs ,BLADDER cancer ,CANCER patients ,URINARY diversion ,NEPHROSTOMY ,CYSTECTOMY ,ILEAL conduit surgery - Published
- 2024
- Full Text
- View/download PDF
13. Defining the Morbidity of Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Adoption of the Comprehensive Complication Index.
- Author
-
Albisinni, Simone, Diamand, Romain, Mjaess, Georges, Aoun, Fouad, Assenmacher, Gregoire, Assenmacher, Christophe, Verhoest, Gregory, Holz, Serge, Naudin, Michel, Ploussard, Guillaume, Mari, Andrea, Minervini, Andrea, Tay, Andrea, Issa, Rami, Roumiguié, Mathieu, Bajeot, Anne Sophie, Simone, Giuseppe, Anceschi, Umberto, Umari, Paolo, and Sridhar, Ashwin
- Subjects
URINARY diversion ,CYSTECTOMY ,SURGICAL robots ,SURGICAL complications ,PATIENTS' attitudes ,CLINICAL trials ,BLADDER cancer - Abstract
Background and Objective: The Clavien–Dindo Classification (CDC) only reports the postoperative complication of highest grade. It is thus of limited value for radical cystectomy, after which patients usually experience multiple complications. The Comprehensive Complication Index (CCI) is a novel scoring system, which incorporates all postoperative events in one single value. The study aimed to adopt the CCI for the evaluation of complications in patients undergoing robot-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD) and explore its advantages in the analysis of the morbidity of RARC with ICUD. Patients and Methods: A multicentric cohort of 959 patients undergoing RARC+ICUD between 2015 and 2020, whose complications are encoded in local prospective registries. Postoperative complications at 30 days were assessed using both the CDC and CCI. The CCI was calculated using an online tool (assessurgery.com). Risk factors for overall, major complications (CDC ≥III), and CCI were evaluated using uni- and multivariable logistic and linear regressions. To analyze the potential advantage of using the CCI in clinical trials, a sample size calculation of a hypothetic clinical trial was performed using as endpoint reduction of morbidity with either the CDC or CCI. Results: Overall, 885 postoperative complications were reported in 507 patients (53%). The CCI improved the definition of postoperative morbidity in 22.6% of patients. Male sex and neobladder were associated with major complications and to a significant increase in CCI on adjusted regressions. In a hypothetical clinical trial, 80 patients would be needed to demonstrate a ten-point reduction in CCI, compared with 186 needed to demonstrate an absolute risk reduction of 20% in overall morbidity using the CDC. Conclusion: CCI improves the evaluation of postoperative morbidity by considering the cumulative aspect of complications compared with the CDC. Implementing the CCI for radical cystectomy would help reducing sample sizes in clinical trials. Clinical Trial Registration number: NCT03049410. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration.
- Author
-
Lonati, Chiara, Afferi, Luca, Mari, Andrea, Minervini, Andrea, Krajewski, Wojciech, Borghesi, Marco, Schulz, Gerald B., Rink, Michael, Montorsi, Francesco, Briganti, Alberto, Colombo, Renzo, Martini, Alberto, Necchi, Andrea, Contieri, Roberto, Hurle, Rodolfo, Umari, Paolo, Zamboni, Stefania, Simeone, Claudio, Soria, Francesco, and Marra, Giancarlo
- Subjects
BLADDER cancer ,CYSTECTOMY ,PROGRESSION-free survival ,LOG-rank test ,IMMUNOTHERAPY - Abstract
Purpose: To compare cancer-specific mortality (CSM) and overall mortality (OM) between immediate radical cystectomy (RC) and Bacillus Calmette–Guérin (BCG) immunotherapy for T1 squamous bladder cancer (BCa). Methods: We retrospectively analysed 188 T1 high-grade squamous BCa patients treated between 1998 and 2019 at fifteen tertiary referral centres. Median follow-up time was 36 months (interquartile range: 19–76). The cumulative incidence and Kaplan–Meier curves were applied for CSM and OM, respectively, and compared with the Pepe–Mori and log-rank tests. Multivariable Cox models, adjusted for pathological findings at initial transurethral resection of bladder (TURB) specimen, were adopted to predict tumour recurrence and tumour progression after BCG immunotherapy. Results: Immediate RC and conservative management were performed in 20% and 80% of patients, respectively. 5-year CSM and OM did not significantly differ between the two therapeutic strategies (Pepe–Mori test p = 0.052 and log-rank test p = 0.2, respectively). At multivariable Cox analyses, pure squamous cell carcinoma (SqCC) was an independent predictor of tumour progression (p = 0.04), while concomitant lympho-vascular invasion (LVI) was an independent predictor of both tumour recurrence and progression (p = 0.04) after BCG. Patients with neither pure SqCC nor LVI showed a significant benefit in 3-year recurrence-free survival and progression-free survival compared to individuals with pure SqCC or LVI (60% vs. 44%, p = 0.04 and 80% vs. 68%, p = 0.004, respectively). Conclusion: BCG could represent an effective treatment for T1 squamous BCa patients with neither pure SqCC nor LVI, while immediate RC should be preferred among T1 squamous BCa patients with pure SqCC or LVI at initial TURB specimen. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy.
- Author
-
Ferro, Matteo, Lucarelli, Giuseppe, de Cobelli, Ottavio, Dolce, Pasquale, Terracciano, Daniela, Musi, Gennaro, Porreca, Angelo, Busetto, Gian Maria, Del Giudice, Francesco, Soria, Francesco, Gontero, Paolo, Cantiello, Francesco, Damiano, Rocco, Crocerossa, Fabio, Abu Farhan, Abdal Rahman, Autorino, Riccardo, Vartolomei, Mihai Dorin, Marchioni, Michele, Mari, Andrea, and Minervini, Andrea
- Subjects
THERAPEUTIC use of antineoplastic agents ,BLADDER tumors ,CYSTECTOMY ,ADJUVANT chemotherapy ,RETROSPECTIVE studies ,CISPLATIN ,CHOLESTEROL - Abstract
The objective of the current research was to explore the potential prognostic value of readily available clinical and pathologic variables in bladder cancer. The novel association found between cholesterol levels and prognosis may provide the rationale for exploring novel treatments. Patients included had histologically confirmed urothelial bladder cancer and were treated with at least 3 cycles of cisplatin-based neoadjuvant chemotherapy before radical cystectomy with lymphadenectomy. A total of 245 patients at low, intermediate and high risk, presenting with 0-1, 2 or 3-4 risk factors, including positive lymph nodes, Hb <12.8, NLR ≥2.7 and cholesterol levels ≥199, were included. Five-year cancer-specific survival rate was 0.67, 0.78 and 0.94 at high, intermediate and low risk, respectively. Total cholesterol levels at the time of cystectomy may represent a commonly assessable prognostic factor and may be incorporated in a clinically meaningful risk-group classification model. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes.
- Author
-
Krajewski, Wojciech, Moschini, Marco, Chorbińska, Joanna, Nowak, Łukasz, Poletajew, Sławomir, Tukiendorf, Andrzej, Afferi, Luca, Teoh, Jeremy Yuen-Chun, Muilwijk, Tim, Joniau, Steven, Tafuri, Alessandro, Antonelli, Alessandro, Cianflone, Francesco, Mari, Andrea, Di Trapani, Ettore, Hendricksen, Kees, Alvarez-Maestro, Mario, Rodríguez-Serrano, Andrea, Simone, Giuseppe, and Zamboni, Stefania
- Subjects
BLADDER cancer ,SURVIVAL rate ,URETHRA ,DISEASE relapse ,IMMUNOTHERAPY ,REGRESSION analysis ,LOG-rank test - Abstract
Purpose: This study was carried out to assess whether a prolonged time between primary transurethral resection of non-muscle-invasive bladder cancer (TURB) and implementation of bacillus Calmette–Guerin (BCG) immunotherapy (time to BCG; TTBCG) is associated with adverse oncological survival in patients with T1 high-grade (HG) non-muscle-invasive bladder cancer (NMIBC). Materials and methods: Data on 429 patients from 13 tertiary care centers with primary T1HG NMIBC treated with reTURB and maintenance BCG between 2001 and 2019 were retrospectively reviewed. Change-point regression was applied following Muggeo's approach. The population was divided into subgroups according to TTBCG, whereas the recurrence-free survival (RFS) and progression-free survival (PFS) were estimated with log-rank tests. Additionally, Cox regression analyses were performed. Due to differences in baseline patient characteristics, propensity-score-matched analysis (PSM) and inverse-probability weighting (IPW) were implemented. Results: The median TTBCG was 95 days (interquartile range (IQR): 71–127). The change-point regression analysis revealed a gradually increasing risk of recurrence with growing TTBCG. The risk of tumor progression gradually increased until a TTBCG of approximately 18 weeks. When the study population was divided into two subgroups (time intervals: ≤ 101 and > 101 days), statistically significant differences were found for both RFS (p = 0.029) and PFS (p = 0.005). Furthermore, in patients with a viable tumor at reTURB, there were no differences in RFS and PFS. After both PSM and IPW, statistically significant differences were found for both RFS and PFS, with worse results for longer TTBCG. Conclusion: This study shows that delaying BCG immunotherapy after TURB of T1HG NMIBC is associated with an increased risk of tumor recurrence and progression. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Stentless florence robotic intracorporeal neobladder (FloRIN), a feasibility prospective randomized clinical trial.
- Author
-
Lambertini, Luca, Di Maida, Fabrizio, Cadenar, Anna, Nardoni, Samuele, Grosso, Antonio Andrea, Valastro, Francesca, Spinelli, Pietro, Fantechi, Riccardo, Tuccio, Agostino, Vittori, Gianni, Mari, Andrea, Masieri, Lorenzo, and Minervini, Andrea
- Subjects
CLINICAL trials ,BLOOD loss estimation ,SURGICAL complications ,LENGTH of stay in hospitals ,KIDNEY transplantation ,KIDNEY physiology ,URINARY diversion - Abstract
Aim of the study was to evaluate perioperative, postoperative and mid-term functional outcomes of Florence intracorporeal neobladder (FloRIN) configuration technique performed with stentless procedure. This single institution randomized 1:1 prospective series included consecutive patients treated with Robot-Assisted Radical Cystectomy (RARC) and FloRIN reconfiguration from January 2021 to February 2022. Postoperative complications were graded according to Clavien Dindo classification and divided in early (<30 days from discharge) and delayed (>30 days). Overall, 63 patients were included in the analysis. Among these 32 (50.8 %) were treated with RARC + stentless FloRIN while 31 (49.2 %) underwent stent placement procedure. No differences were found in terms of baseline characteristics between the two groups. Stentless procedure was associated with significant shorter console time 328 vs 374 min (p = 0.04) and lower estimated blood loss (EBL) 330 vs 350 ml (p = 0.04) comparing to stent group. As regards perioperative features, no significant differences were recorded in terms of canalization (p = 0.58) and time to drainage removal (p = 0.11) while a shorter length of hospital stay was found in case of stentless procedure (p = 0.04). Early postoperative complications Clavien ≥ 3a occurred in 9.3 % and 12.9 % of patients while delayed major complications were recorded in the 3.1 % and 9.6 % of patients treated with stentless and stent FloRIN, respectively (p = 0.09). As regards the mid-term functional outcomes, no differences were found in terms of kidney function loss in both 3rd and 6th month assessment (p = 0.13 and p = 0.14, respectively). In conclusion, Stentless FloRIN is a feasible and safe IntraCorporeal Neobladder technique, as confirmed by the worthy functional and perioperative outcomes achieved in comparison with the standard FloRIN ureteral management strategy. • RARC with ICNs showed several advantages when performed with stentless technique • Stentless FloRIN was associated with lower console time, EBL and hospitalization • No significant differences in terms of early and delayed complications were recorded between stented and stentless procedures. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Editorial Comment from Dr Tellini et al. to Bladder cancer prospective cohort study on high‐risk non‐muscle invasive bladder cancer after photodynamic diagnosis‐assisted transurethral resection of the bladder tumor (BRIGHT study).
- Author
-
Tellini, Riccardo, Mari, Andrea, and Minervini, Andrea
- Subjects
- *
BLADDER cancer , *CANCER invasiveness , *EDITORIAL writing , *COHORT analysis , *LONGITUDINAL method ,TUMOR surgery - Abstract
High-risk non-muscle-invasive bladder cancer (NMIBC) is a common and heterogeneous entity and it often represents a clinical dilemma for urologists due to need to balance the risk of recurrence and progression with the risk of overtreatment (i.e., early radical cystectomy).1 Transurethral resection of bladder tumor (TURBT) is the standard diagnostic and therapeutic approach to NMIBC. Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study). Editorial Comment from Dr Tellini et al. to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study). [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
19. Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis.
- Author
-
Del Giudice, Francesco, Flammia, Rocco Simone, Chung, Benjamin I., Moschini, Marco, Pradere, Benjamin, Mari, Andrea, Soria, Francesco, Albisinni, Simone, Krajewski, Wojciech, Szydełko, Tomasz, Laukhtina, Ekaterina, D'Andrea, David, Gallioli, Andrea, Mertens, Laura S., Maggi, Martina, Sciarra, Alessandro, Salciccia, Stefano, Ferro, Matteo, Scornajenghi, Carlo Maria, and Asero, Vincenzo
- Subjects
DRUG efficacy ,MULTIPLE regression analysis ,NON-muscle invasive bladder cancer ,COMPARATIVE studies ,BCG vaccines ,KAPLAN-Meier estimator ,DESCRIPTIVE statistics ,PROGRESSION-free survival ,IMMUNOTHERAPY - Abstract
Simple Summary: Intravesical immunotherapy with bacillus Calmette–Guerin (BCG) is the standard therapy for high-risk non-muscle invasive bladder cancer. Different BCG strains are currently available and the superiority of any BCG strain over another could not be demonstrated yet. We compared the efficacy of two BCG strains: RIVM and TICE, respectively. In this propensity-score matched cohort study, we showed no particular survival benefit of TICE vs RIVM in the case of high-risk disease. Nevertheless, stratifying our data for re-staging procedures and for those who received BCG maintenance, we identified BCG TICE to improve RFS independently. Herein, we corroborated the importance of performing a routine secondary resection followed by an adequate maintenance course of BCG. Future larger prospective randomized head-to-head trials are needed to further elucidate this important topic, especially in this era of BCG shortage. Background: Intravesical immunotherapy with bacillus Calmette–Guerin (BCG) is the standard therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The superiority of any BCG strain over another could not be demonstrated yet. Methods: Patients with NMIBCs underwent adjuvant induction ± maintenance schedule of intravesical immunotherapy with either BCG TICE or RIVM at two high-volume tertiary institutions. Only BCG-naïve patients and those treated with the same strain over the course of follow-up were included. One-to-one (1:1) propensity score matching (PSM) between the two cohorts was utilized to adjust for baseline demographic and tumor characteristics imbalances. Kaplan–Meier estimates and multivariable Cox regression models according to high-risk NMIBC prognostic factors were implemented to address survival differences between the strains. Sub-group analysis modeling of the influence of routine secondary resection (re-TUR) in the setting of the sole maintenance adjuvant schedule for the two strains was further performed. Results: 852 Ta-T1 NMIBCs (n = 719, 84.4% on TICE; n = 133, 15.6% on RIVM) with a median of 53 (24–77) months of follow-up were reviewed. After PSM, no differences at 5-years RFS, PFS, and CSS at both Kaplan–Meier and Cox regression analyses were detected for the whole cohort. In the sub-group setting of full adherence to European/American Urology Guidelines (EAU/NCCN), BCG TICE demonstrated longer 5-years RFS compared to RIVM (68% vs. 43%, p = 0.008; HR: 0.45 95% CI 0.25–0.81). Conclusion: When routinely performing re-TUR followed by a maintenance BCG schedule, TICE was superior to RIVM for RFS outcomes. However, no significant differences were detected for PFS and CSS, respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding.
- Author
-
Antonelli, Luca, Wendel‐Garcia, Pedro David, Deforth, Manja, Afferi, Luca, Leonardo, Costantino, Esperto, Francesco, Borghesi, Marco, Antonelli, Alessandro, Tully, Karl, Umari, Paolo, Albisinni, Simone, Mari, Andrea, Pichler, Renate, Claps, Francesco, Teoh, Jeremy Yuen‐Chun, Roumiguié, Mathieu, Schulz, Gerald Bastian, Orecchia, Luca, Soria, Francesco, and Roupret, Morgan
- Abstract
Objectives Materials and Methods Results Conclusions To assess the risk of venous thromboembolic events (VTEs) and bleeding with or without thromboprophylaxis during neoadjuvant chemotherapy in bladder cancer patients scheduled for radical cystectomy.We conducted a retrospective cohort study in 4886 patients with non‐metastatic bladder cancer undergoing cystectomy across 28 centres in 13 countries between 1990 and 2021. Inverse probability weighting analyses were performed to estimate the effect of thromboprophylaxis on VTE and bleeding.In 147 patients (3%) VTEs were recorded within the first year. These occurred a median (interquartile range [IQR]) of 127 (82–198) days after bladder cancer diagnosis. Bleeding events occurred in 131 patients (3%) within the first year. These occurred a median (IQR) of 101 (83–171) days after cancer diagnosis. In inverse probability weighting analyses, compared to patients without thromboprophylaxis during chemotherapy, patients with thromboprophylaxis had not only a lower risk of VTE (hazard ratio [HR] 0.32, 95% confidence interval [CI] 0.12–0.81; P = 0.016) but also a lower bleeding risk (HR 0.03, 95% CI 0.09–0.12; P <0.0001). The retrospective nature of the study was its main limitation.In this retrospective analysis, the benefit of thromboprophylaxis during neoadjuvant chemotherapy before cystectomy is in line with data from randomised trials in other malignancies. Our data suggest thromboprophylaxis is protective against VTEs and should be the standard of care during neoadjuvant chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
- Author
-
Zlotta, Alexandre R, Ballas, Leslie K, Niemierko, Andrzej, Lajkosz, Katherine, Kuk, Cynthia, Miranda, Gus, Drumm, Michael, Mari, Andrea, Thio, Ethan, Fleshner, Neil E, Kulkarni, Girish S, Jewett, Michael A S, Bristow, Robert G, Catton, Charles, Berlin, Alejandro, Sridhar, Srikala S, Schuckman, Anne, Feldman, Adam S, Wszolek, Matthew, and Dahl, Douglas M
- Subjects
- *
BLADDER cancer , *CANCER invasiveness , *PROPENSITY score matching , *CYSTECTOMY , *TRANSURETHRAL resection of bladder , *UROTHELIUM , *BLADDER obstruction , *RANDOMIZED controlled trials - Abstract
Previous randomised controlled trials comparing bladder preservation with radical cystectomy for muscle-invasive bladder cancer closed due to insufficient accrual. Given that no further trials are foreseen, we aimed to use propensity scores to compare trimodality therapy (maximal transurethral resection of bladder tumour followed by concurrent chemoradiation) with radical cystectomy. This retrospective analysis included 722 patients with clinical stage T2–T4N0M0 muscle-invasive urothelial carcinoma of the bladder (440 underwent radical cystectomy, 282 received trimodality therapy) who would have been eligible for both approaches, treated at three university centres in the USA and Canada between Jan 1, 2005, and Dec 31, 2017. All patients had solitary tumours less than 7 cm, no or unilateral hydronephrosis, and no extensive or multifocal carcinoma in situ. The 440 cases of radical cystectomy represent 29% of all radical cystectomies performed during the study period at the contributing institutions. The primary endpoint was metastasis-free survival. Secondary endpoints included overall survival, cancer-specific survival, and disease-free survival. Differences in survival outcomes by treatment were analysed using propensity scores incorporated in propensity score matching (PSM) using logistic regression and 3:1 matching with replacement and inverse probability treatment weighting (IPTW). In the PSM analysis, the 3:1 matched cohort comprised 1119 patients (837 radical cystectomy, 282 trimodality therapy). After matching, age (71·4 years [IQR 66·0–77·1] for radical cystectomy vs 71·6 years [64·0–78·9] for trimodality therapy), sex (213 [25%] vs 68 [24%] female; 624 [75%] vs 214 [76%] male), cT2 stage (755 [90%] vs 255 [90%]), presence of hydronephrosis (97 [12%] vs 27 [10%]), and receipt of neoadjuvant or adjuvant chemotherapy (492 [59%] vs 159 [56%]) were similar between groups. Median follow-up was 4·38 years (IQR 1·6–6·7) versus 4·88 years (2·8–7·7), respectively. 5-year metastasis-free survival was 74% (95% CI 70–78) for radical cystectomy and 75% (70–80) for trimodality therapy with IPTW and 74% (70–77) and 74% (68–79) with PSM. There was no difference in metastasis-free survival either with IPTW (subdistribution hazard ratio [SHR] 0·89 [95% CI 0·67–1·20]; p=0·40) or PSM (SHR 0·93 [0·71–1·24]; p=0·64). 5-year cancer-specific survival for radical cystectomy versus trimodality therapy was 81% (95% CI 77–85) versus 84% (79–89) with IPTW and 83% (80–86) versus 85% (80–89) with PSM. 5-year disease-free survival was 73% (95% CI 69–77) versus 74% (69–79) with IPTW and 76% (72–80) versus 76% (71–81) with PSM. There were no differences in cancer-specific survival (IPTW: SHR 0·72 [95% CI 0·50–1·04]; p=0·071; PSM: SHR 0·73 [0·52–1·02]; p=0·057) and disease-free survival (IPTW: SHR 0·87 [0·65–1·16]; p=0·35; PSM: SHR 0·88 [0·67–1·16]; p=0·37) between radical cystectomy and trimodality therapy. Overall survival favoured trimodality therapy (IPTW: 66% [95% CI 61–71] vs 73% [68–78]; hazard ratio [HR] 0·70 [95% CI 0·53–0·92]; p=0·010; PSM: 72% [69–75] vs 77% [72–81]; HR 0·75 [0·58–0·97]; p=0·0078). Outcomes for radical cystectomy and trimodality therapy were not statistically different among centres for cancer-specific survival and metastasis-free survival (p=0·22–0·90). Salvage cystectomy was done in 38 (13%) trimodality therapy patients. Pathological stage in the 440 radical cystectomy patients was pT2 in 124 (28%), pT3–4 in 194 (44%), and 114 (26%) node positive. The median number of nodes removed was 39, the soft tissue positive margin rate was 1% (n=5), and the perioperative mortality rate was 2·5% (n=11). This multi-institutional study provides the best evidence to date showing similar oncological outcomes between radical cystectomy and trimodality therapy for select patients with muscle-invasive bladder cancer. These results support that trimodality therapy, in the setting of multidisciplinary shared decision making, should be offered to all suitable candidates with muscle-invasive bladder cancer and not only to patients with significant comorbidities for whom surgery is not an option. Sinai Health Foundation, Princess Margaret Cancer Foundation, Massachusetts General Hospital. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Fighting the 'tobacco epidemic' - A call to action to identify Targeted Intervention Points (TIPs) for better counseling patients with urothelial cancer.
- Author
-
Cacciamani, Giovanni E., Matulewicz, Richard S., Kumar, Raj, Teoh, Jeremy Yuen-Chun, Mari, Andrea, Pradere, Benjamin, Gomez Rivas, Juan, Necchi, Andrea, Kumar Pal, Sumanta, Ribal, Maria J., Shariat, Shahrokh, Rink, Michael, and SMART (Stop sMoking for Advance Rehabilitation Treatments) Urology Working Group
- Subjects
- *
TRANSITIONAL cell carcinoma , *TOBACCO , *CANCER patients , *TOBACCO use , *BLADDER cancer , *MEDICAL education - Abstract
The association between tobacco use and urothelial cancer of the bladder is well known. Given the worsening tobacco epidemic, here we make the case for systematic targeted points of intervention for urologists and other professionals to intervene against bladder cancer. Awareness of contemporary checkpoints where we can intervene for counseling patients may help medical education in a tobacco-pandemic difficult setting. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis.
- Author
-
Laukhtina, Ekaterina, Mori, Keiichiro, D'Andrea, David, Moschini, Marco, Abufaraj, Mohammad, Soria, Francesco, Mari, Andrea, Krajewski, Wojciech, Albisinni, Simone, Teoh, Jeremy Yuen-Chun, Quhal, Fahad, Sari Motlagh, Reza, Mostafaei, Hadi, Katayama, Satoshi, Grossmann, Nico С., Rajwa, Pawel, Enikeev, Dmitry, Zimmermann, Kristin, Fajkovic, Harun, and Glybochko, Petr
- Subjects
- *
BLADDER cancer , *SURVIVAL rate , *CYSTECTOMY , *TREATMENT effectiveness , *SURVIVAL analysis (Biometry) , *WOMEN patients , *META-analysis , *SYSTEMATIC reviews , *CANCER relapse , *DISEASE incidence ,BLADDER tumors - Abstract
We aimed to conduct a systematic review and meta-analysis assessing the incidence and risk factors of urethral recurrence (UR) as well as summarizing data on survival outcomes in patients with UR after radical cystectomy (RC) for bladder cancer. The MEDLINE and EMBASE databases were searched in February 2021 for studies of patients with UR after RC. Incidence and risk factors of UR were the primary endpoints. The secondary endpoint was survival outcomes in patients who experienced UR. Twenty-one studies, comprising 9,435 patients, were included in the quantitative synthesis. Orthotopic neobladder (ONB) diversion was associated with a decreased probability of UR compared to non-ONB (pooled OR: 0.44, 95% CI: 0.31-0.61, P < 0.001) and male patients had a significantly higher risk of UR compared to female patients (pooled OR: 3.16, 95% CI: 1.83-5.47, P < 0.001). Among risk factors, prostatic urethral or prostatic stromal involvement (pooled HR: 5.44, 95% CI: 3.58-8.26, P < 0.001; pooled HR: 5.90, 95% CI: 1.82-19.17, P = 0.003, respectively) and tumor multifocality (pooled HR: 2.97, 95% CI: 2.05-4.29, P < 0.001) were associated with worse urethral recurrence-free survival. Neither tumor stage (P = 0.63) nor CIS (P = 0.72) were associated with worse urethral recurrence-free survival. Patients with UR had a 5-year CSS that varied from 47% to 63% and an OS - from 40% to 74%; UR did not appear to be related to worse survival outcomes. Male patients treated with non-ONB diversion as well as patients with prostatic involvement and tumor multifocality seem to be at the highest risk of UR after RC. Risk-adjusted standardized surveillance protocols should be developed into clinical practice after RC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy
- Author
-
Nicola Longo, Daniela Terracciano, Francesco Del Giudice, Giuseppe Lucarelli, Angelo Porreca, Pasquale Ditonno, Angelo Luciano, Carlo Buonerba, Alessandro Antonelli, Vincenzo Caputo, Rocco Damiano, Pasquale Dolce, Michele Marchioni, Fabio Crocerossa, Paolo Gontero, Stefania Zamboni, Matteo Manfredi, Antonio Verde, Michele Battaglia, Dario Ribera, Francesco Porpiglia, Gennaro Musi, Francesco Cantiello, Andrea Minervini, Felice Crocetto, Ottavio De Cobelli, Giuseppe Celentano, Vincenzo Cosimato, Mihai Dorin Vartolomei, Nicolae Crisan, Andrea Mari, Giorgio Ivan Russo, Abdal Rahman Abu Farhan, Francesco Greco, Francesco Soria, Francesco Chiancone, Luca Scafuri, Paola Del Prete, Rodolfo Hurle, Pietro De Placido, Giuseppe Di Lorenzo, Sergio Facchini, Matteo Ferro, Riccardo Autorino, Sisto Perdonà, Gian Maria Busetto, Ferro, Matteo, Lucarelli, Giuseppe, de Cobelli, Ottavio, Dolce, Pasquale, Terracciano, Daniela, Musi, Gennaro, Porreca, Angelo, Busetto, Gian Maria, Del Giudice, Francesco, Soria, Francesco, Gontero, Paolo, Cantiello, Francesco, Damiano, Rocco, Crocerossa, Fabio, Abu Farhan, Abdal Rahman, Autorino, Riccardo, Vartolomei, Mihai Dorin, Marchioni, Michele, Mari, Andrea, Minervini, Andrea, Longo, Nicola, Celentano, Giuseppe, Chiancone, Francesco, Perdonà, Sisto, Del Prete, Paola, Ditonno, Pasquale, Battaglia, Michele, Zamboni, Stefania, Antonelli, Alessandro, Greco, Francesco, Russo, Giorgio Ivan, Hurle, Rodolfo, Crisan, Nicolae, Manfredi, Matteo, Porpiglia, Francesco, Ribera, Dario, De Placido, Pietro, Facchini, Sergio, Scafuri, Luca, Verde, Antonio, Di Lorenzo, Giuseppe, Cosimato, Vincenzo, Luciano, Angelo, Caputo, Vincenzo Francesco, Crocetto, Felice, and Buonerba, Carlo
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,030232 urology & nephrology ,Cystectomy ,Neoadjuvant chemotherapy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Survival rate ,Aged ,Retrospective Studies ,Cisplatin ,Chemotherapy ,Bladder cancer ,business.industry ,Cholesterol ,Combination chemotherapy ,General Medicine ,Middle Aged ,medicine.disease ,Radical cystectomy ,Urinary Bladder Neoplasms ,chemistry ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Female ,Lymphadenectomy ,business ,medicine.drug - Abstract
The objective of the current research was to explore the potential prognostic value of readily available clinical and pathologic variables in bladder cancer. The novel association found between cholesterol levels and prognosis may provide the rationale for exploring novel treatments. Patients included had histologically confirmed urothelial bladder cancer and were treated with at least 3 cycles of cisplatin-based neoadjuvant chemotherapy before radical cystectomy with lymphadenectomy. A total of 245 patients at low, intermediate and high risk, presenting with 0-1, 2 or 3-4 risk factors, including positive lymph nodes, Hb 12.8, NLR ≥2.7 and cholesterol levels ≥199, were included. Five-year cancer-specific survival rate was 0.67, 0.78 and 0.94 at high, intermediate and low risk, respectively. Total cholesterol levels at the time of cystectomy may represent a commonly assessable prognostic factor and may be incorporated in a clinically meaningful risk-group classification model.Lay abstract This present study assessed a large group of patients with urothelial bladder cancer treated with chemotherapy followed by radical cystectomy, to capture the predictive power of commonly collected clinical, pathological and biochemical factors. The design of the study highlighted that higher cholesterol levels at the time of cystectomy were associated with shorter cancer-specific survival. This finding suggests that high blood-cholesterol levels truly have a negative influence on surviving cancer. In conclusion, total cholesterol levels at the time of cystectomy may represent a commonly assessable prognostic factor and could be incorporated into a clinically meaningful and valuable risk-group classification model.
- Published
- 2021
25. Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis
- Author
-
Francesco Del Giudice, Vincenzo Asero, Eugenio Bologna, Carlo Maria Scornajenghi, Dalila Carino, Virginia Dolci, Pietro Viscuso, Stefano Salciccia, Alessandro Sciarra, David D’Andrea, Benjamin Pradere, Marco Moschini, Andrea Mari, Simone Albisinni, Wojciech Krajewski, Tomasz Szydełko, Bartosz Małkiewicz, Łukasz Nowak, Ekaterina Laukhtina, Andrea Gallioli, Laura S. Mertens, Gautier Marcq, Alessia Cimadamore, Luca Afferi, Francesco Soria, Keiichiro Mori, Karl Heinrich Tully, Renate Pichler, Matteo Ferro, Octavian Sabin Tataru, Riccardo Autorino, Simone Crivellaro, Felice Crocetto, Gian Maria Busetto, Satvir Basran, Michael L. Eisenberg, Benjamin Inbeh Chung, Ettore De Berardinis, Del Giudice, Francesco, Asero, Vincenzo, Bologna, Eugenio, Scornajenghi, Carlo Maria, Carino, Dalila, Dolci, Virginia, Viscuso, Pietro, Salciccia, Stefano, Sciarra, Alessandro, D'Andrea, David, Pradere, Benjamin, Moschini, Marco, Mari, Andrea, Albisinni, Simone, Krajewski, Wojciech, Szydełko, Tomasz, Małkiewicz, Bartosz, Nowak, Łukasz, Laukhtina, Ekaterina, Gallioli, Andrea, Mertens, Laura S, Marcq, Gautier, Cimadamore, Alessia, Afferi, Luca, Soria, Francesco, Mori, Keiichiro, Tully, Karl Heinrich, Pichler, Renate, Ferro, Matteo, Tataru, Octavian Sabin, Autorino, Riccardo, Crivellaro, Simone, Crocetto, Felice, Busetto, Gian Maria, Basran, Satvir, Eisenberg, Michael L, Chung, Benjamin Inbeh, and De Berardinis, Ettore
- Subjects
network meta-analysi ,Cancer Research ,Oncology ,non-muscle invasive bladder cancer ,bladder cancer ,BCG immunotherapy ,BCG strain ,network meta-analysis ,recurrence rate - Abstract
Background: In an era of Bacillus of Calmette-Guérin (BCG) shortages, the comparative efficacy from different adjuvant intravesical BCG strains in non-muscle invasive bladder cancer (NMIBC) has not been clearly elucidated. We aim to compare, through a systematic review and meta-analysis, the cumulative BC recurrence rates and the best efficacy profile of worldwide available BCG strains over the last forty years. Methods: PubMed, Scopus, Web of Science, Embase, and Cochrane databases were searched from 1982 up to 2022. A meta-analysis of pooled BC recurrence rates was stratified for studies with ≤3-y vs. >3-y recurrence-free survival (RFS) endpoints and the strain of BCG. Sensitivity analysis, sub-group analysis, and meta-regression were implemented to investigate the contribution of moderators to heterogeneity. A random-effect network meta-analysis was performed to compare BCG strains on a multi-treatment level. Results: In total, n = 62 series with n = 15,412 patients in n = 100 study arms and n = 10 different BCG strains were reviewed. BCG Tokyo 172 exhibited the lowest pooled BC recurrence rate among studies with ≤3-y RFS (0.22 (95%CI 0.16–0.28). No clinically relevant difference was noted among strains at >3-y RFS outcomes. Sub-group and meta-regression analyses highlighted the influence of NMIBC risk-group classification and previous intravesical treated categories. Out of the n = 11 studies with n = 7 BCG strains included in the network, BCG RIVM, Tice, and Tokyo 172 presented with the best-predicted probability for efficacy, yet no single strain was significantly superior to another in preventing BC recurrence risk. Conclusion: We did not identify a BCG stain providing a clinically significant lower BC recurrence rate. While these findings might discourage investment in future head-to-head randomized comparison, we were, however, able to highlight some potential enhanced benefits from the genetically different BCG RIVM, Tice, and Tokyo 172. This evidence would support the use of such strains for future BCG trials in NMIBCs.
- Published
- 2023
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.